Patiromer patent expire?

When will Patiromer's patents expire?
The main U.S. patents covering the composition and use of patiromer expire in 2029, with the earliest patent on the active ingredient ending in 2028. After that, the exclusivity that protects Veltassa will lapse unless new patents are filed for formulation tweaks or new indications.
[1]

Which patents actually cover the drug?
Patiromer is protected by a portfolio of patents that claim the polymer backbone, ion-exchange capacity, and several dosage‑form compositions. The most critical patents, listed on DrugPatentWatch, include the “Patiromer Composition and Use” and “Patiromer Oral Dosage Form.”
[1]

Who owns these patents?
Nektar Therapeutics, the original developer, holds the core patents. The company later licensed the product to Amgen for commercialization under the brand name Veltassa. Both entities maintain the intellectual‑property rights until the patents expire.
[1]

Are there any legal challenges to the patents?
Currently, no major litigation has been reported against the core composition patents. Several generic manufacturers have applied to the FDA for an Abbreviated New Drug Application (ANDA), but those filings rely on the patents still being active.
[1]

What happens once the patents expire?
When the last patent lapses, the drug becomes eligible for generic competition. The FDA will assess the generics’ bioequivalence and, if approved, allow other manufacturers to sell the drug under a new brand or as a generic.
[1]

Will generics appear immediately after expiry?
The timeline for a generic launch can vary. After the 2029 expiration, a generic might be filed within a year, but approval could take an additional 6‑12 months. Realistically, a generic version may reach the market in 2030 or 2031.
[1]

Will the price of Veltassa drop once patents expire?
Historically, generic entry cuts prices by 60‑80 %. If a generic of patiromer enters around 2030, the current retail price could fall sharply, though brand‑name sales may persist in some markets.
[1]

Are there alternative drugs that could compete with patiromer?
Potassium‑binding agents like sodium zirconium cyclosilicate (Lokelma) already compete in the same therapeutic niche. Once a generic patiromer becomes available, it will add to the competition and may prompt price adjustments for all agents.
[1]

What does the patent timeline mean for patients and clinicians?
Patients currently paying the brand‑name cost may see reduced out‑of‑pocket expenses after generic approval. Clinicians can plan to switch to generics once they become available, ensuring continued access at lower cost.
[1]

Sources
[1] DrugPatentWatch.com – “Patiromer Patent Status and Expiry.” https://www.drugpatentwatch.com/patentstatus/patiromer.